Characterizing CDK12-Mutated Prostate Cancers.

PURPOSE: CDK12 aberrations have been reported as a biomarker of response to immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). Herein, we characterize CDK12-mutated mCRPC, presenting clinical, genomic, and tumor-infiltrating lymphocyte data. EXPERIMENTAL DESIGN: Patients with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Rescigno, Pasquale, Gurel, Bora, Pereira, Rita, Crespo, Mateus, Rekowski, Jan, Rediti, Mattia, Barrero, Maialen, Mateo, Joaquin, Bianchini, Diletta, Messina, Carlo, Fenor de la Maza, Maria D., Chandran, Khobe, Carmichael, Juliet, Guo, Christina, Paschalis, Alec, Sharp, Adam, Seed, George, Figueiredo, Ines, Lambros, Maryou, Miranda, Susana, Ferreira, Ana, Bertan, Claudia, Riisnaes, Ruth, Porta, Nuria, Yuan, Wei, Carreira, Suzanne, de Bono, Johann S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7855716/
https://ncbi.nlm.nih.gov/pubmed/32988971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-2371
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados